Clinical Trial: ALLIANCE A031704

ALLIANCE A031704

Status: Closed

NCT#03793166

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Eligible for screening study DCP 001

A031704 closed to accrual effective May 15, 2024.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved